By Dee Kotak, M.D.
Our recent analysis of MAP Pharmaceuticals (MAPP) highlighted the market potential of the orally inhaled Levadex for the treatment of acute migraine and the high likelihood of success on the upcoming PDUFA date. Allergan (AGN) and MAP on Tuesday evening jointly announced that they have entered into a definitive merger agreement, whereby AGN will acquire 100% of the shares of MAP Pharmaceuticals for a price of $25.00 per share -- or a total equity value of approximately $958 million on a fully diluted basis.
The surprise is not necessarily in the buyout, but in the timing ahead of the April PDUFA, with the offer not contingent upon FDA approval. It's common for the share price of an acquiring company to fall with the announcement of a buyout (cash outlay), but we see Levadex strengthening the Allergan migraine/neurology portfolio and adding significantly to the Allergan bottom line over the next few years.
While the offer of $25.00 per share represents a 60% premium to Tuesday night's closing price, Allergan has made an astute business move as MAPP has about $100 million in cash, and Allergan would have to pay MAP $77 million in milestone payments on Levadex approval. Furthermore, for the reasons outlined in the previous article, AGN is not taking on undue risk given the high probability of approval. We are of the view that Levadex will add significantly to AGN revenues and profits, as Allergan already plays a role in the migraine treatment space with Botox; cost synergies should be considerable.
Although follow-on indications in adolescents and cluster headaches can be quickly achieved at low cost, the real immediate value driver is the 25% of the 4 million U.S. adult acute migraine population that does not respond to triptans. Capturing just 15% of this population could lead to revenue of $600 million and a conservative total of $1.2 billion including the E.U. and rest of the world. Uptake of Levadex will be fast due to the high dissatisfaction with the current treatment paradigm, leading to a steep initial sales curve. Levadex future revenues could comfortably add $1 in EPS for Allergan based on the company's current ~20% profit margin (Levadex should improve on this significantly), making the billion-dollar acquisition a bargain.
Allergan is hosting a conference call that started at 11:00 a.m. ET. And you can read PropThink's original MAPP report, which was published in early January and has returned 60% following Tuesday's announcement.
Disclaimer: PropThink is a team of editors, analysts, and writers. This article was written by Dee Kotak, MD. We did not receive compensation for this article, and we have no business relationship with any company whose stock is mentioned in this article. Use of PropThink’s research is at your own risk. You should do your own research and due diligence before making any investment decision with respect to securities covered herein.You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. Our full disclaimer is available at www.propthink.com/disclaimer.
Disclosure: I am long MAPP.